 |
||
 |
 |
 |
 |
||
|
Pharminox was formed in 2002 as a spin-out from Oxford University. We are focused on the discovery and development of novel small molecule drugs for the treatment of cancer. In early 2004, Malcolm Stevens, then director of the Cancer Research UK Experimental Cancer Chemotherapy Group, joined Pharminox as Chief Scientific Officer. Our discovery activities are now based at our new laboratories at the BioCity facility in the centre of Nottingham. We have world class expertise in medicinal chemistry and our approach... |
| Read more |
RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl] acridinium methosulfate)
RHPS4 has been identified as a potent lead candidate from our programme of telomere targeted agents as an approach to cancer therapy. Telomeres are repetitive DNA sequences ("telomeric DNA") and associated proteins that cap the ends of chromosomes ("capping" proteins) and protect them against end to end fusion and nuclease degradation.
Our current pipeline
We have a mechanistically and structurally diverse portfolio of small molecules which have the potential to be first in class with multiple applicability across some of the most common types of cancer.
